The labeling in the CBD (cannabidiol) market is an important subject to discuss, the products containing CBD have gained space in the market by helping to combat different conditions caused by contemporary life. Confirmations of its benefits are currently spread across various media, making this ingredient more and more in demand.
However, in a recent survey published in the JAMA (Journal of the American Medical Association), it was found that many of the products sold online containing CBD were withdrawn from the market by mislabeling. Some labels make medical claims not certified by the FDA and others mention the wrong amount of ingredients and potency.
University of Pennsylvania researcher Marcel Bonn-Miller, along with associates from Americans for Safe Access and Johns Hopkins University, tested 84 American products containing CBD in 2016, and the results found that 69% were labeled incorrectly. It was also found that in the category of tinctures the precision of the label was higher, where 55% of these products tested negative.
* It was considered that any product whose potency varied by more than 10% of what its labeling indicated, would be incorrect.
The Importance of Regulation
Although not indicated on the label, some of these products had small levels of THC, more than permitted by law. For this reason, the researchers emphasize the need for federal and state regulatory agencies to take measures to ensure the accuracy of labels on consumer products.
CBD does not present abusive risks or adverse consequences when used in large quantities, but this study represents a warning to emerging CBD Industries and State and Federal Regulators who refuse to take steps to regularize CBD products to ensure the quality and safety of its consumers.
However, the research has some caveats. For example, the study objects used were compared in the autumn of 2016, with the Cannabis market moving so fast, these products may have been reformulated, or at least not even exist in 2021.
This research published by JAMA shares similar studies from past years done by FDA officials, who tested products with CBD and also found their bad labeling. At the end of 2017, they sent letters to some manufacturers of selected products, warning them to remove any claim that attributes the cure of a specific medical condition, incorrect quantity, and appealing advertisements.
Products containing cannabidiol help doctors and patients on a daily basis, more and more often and meeting greater demand. However, these consumers operate in constant uncertainty, where they are not sure about the origin of the products they use, their quality, and the precision of their labels.
For this reason, the assistance of regulating and inspection bodies is so important, so that there is a quality standard for consumers, where more and more people are benefited by CBD.
Evona's mission is to build a world where people care deeply about what they consume. We seek to create a future where anyone can benefit from healthy products in a practical way.
EvonaMD is our medical platform created with the purpose of educating the market and assisting anyone who is interested in starting treatment with CBD products. We help our patients obtain a medical prescription and purchase their first CBD product. Sign up for our newsletter to receive our articles and find out when we launch the patient program.
This information has not been reviewed by ANVISA and should not be used to diagnose, treat or cure any condition. If you have questions, please consult a specialist doctor.